Last updated: September 9, 2026
Atrasentan hydrochloride is an investigational, oral endothelin A receptor antagonist being developed by Novartis for immunoglobulin A nephropathy (IgAN), a chronic kidney disease that can progress to kidney failure. The asset has no FDA-approved product, no commercial revenue, and no Orange Book listing. Its value depends primarily on the Phase 3 ALIGN data package, regulatory approval, differentiation from targeted IgAN therapies, and the ability to establish a durable position in combination treatment.
Novartis acquired atrasentan through its $3.2 billion acquisition of Chinook Therapeutics in 2023. The program is strategically important because it targets proteinuria, a recognized risk marker for renal decline, while adding an endothelin pathway to the existing treatment approaches used in IgAN.[1]
What is atrasentan hydrochloride and how does it work?
Atrasentan hydrochloride is the hydrochloride salt of atrasentan, a selective endothelin A receptor antagonist. Endothelin A signaling contributes to renal vasoconstriction, inflammation, fibrosis and glomerular injury. Blocking the receptor is intended to reduce albuminuria and slow loss of kidney function.
The drug was previously known as ABT-627 and was developed by Abbott Laboratories and later AbbVie in multiple disease areas, including diabetic nephropathy and oncology. Earlier development programs did not produce an approved commercial product. Chinook obtained rights to continue development in kidney disease, with IgAN becoming the lead indication.[2]
What disease is atrasentan targeting?
IgAN is caused by deposition of abnormal immunoglobulin A-containing immune complexes in the kidney. Patients may have persistent proteinuria, declining estimated glomerular filtration rate and eventual kidney failure.
The commercial opportunity is supported by:
- A substantial diagnosed and underdiagnosed patient population.
- Long treatment duration for patients at risk of progression.
- High medical costs associated with dialysis and kidney transplantation.
- Expansion of disease-modifying treatment options.
- The potential use of multiple agents with complementary mechanisms.
Atrasentan is expected to be used in patients who remain at risk despite optimized supportive care, including renin-angiotensin system blockade and, in many cases, sodium-glucose cotransporter-2 therapy.
What is the FDA and regulatory status of atrasentan?
Atrasentan is not FDA approved. It has not received an FDA approval date, commercial label or New Drug Application approval.
Novartis is developing atrasentan in the global Phase 3 ALIGN study in patients with IgAN. The trial evaluates proteinuria reduction and longer-term kidney outcomes. Earlier-stage studies indicated reductions in proteinuria, supporting continued development in the disease.[3]
What was the ALIGN Phase 3 trial?
ALIGN is a randomized, double-blind, placebo-controlled Phase 3 study evaluating atrasentan in adults with IgAN who remain at risk of disease progression despite supportive care. The study was designed around proteinuria reduction as an intermediate endpoint and kidney function outcomes over longer follow-up.
The main commercial relevance of ALIGN is its potential to establish atrasentan as:
- A disease-modifying therapy for higher-risk IgAN.
- A combination option alongside supportive care.
- A competitor to targeted-release budesonide and sparsentan.
- A therapy with broader use than immunosuppressive regimens.
Positive proteinuria data alone may support an accelerated regulatory path if FDA accepts the endpoint as reasonably predictive of clinical benefit. Continued kidney function data would be important for conventional approval and payer positioning.
When could atrasentan lose exclusivity?
Atrasentan has no approved product exclusivity period because it has not reached the market. Any future exclusivity would depend on FDA approval, the approved indication, orphan-drug status, patent coverage and the regulatory pathway.
| Exclusivity category |
Current position |
| FDA approval |
None |
| Orange Book listing |
None |
| New chemical entity exclusivity |
Not started |
| Orphan-drug exclusivity |
No confirmed commercial period without approval |
| Pediatric exclusivity |
None |
| Patent term extension |
None granted for a marketed atrasentan product |
| Generic filing window |
Not applicable before approval |
A future approval could provide five years of new chemical entity exclusivity if FDA determines that the product qualifies as a new active moiety. Orphan-drug exclusivity could provide seven years for an approved orphan indication, subject to the statutory requirements. These periods would run independently of patent terms, although their practical value would depend on the final label and patent estate.
What patents protect atrasentan?
The original composition-of-matter patents for atrasentan were filed during its earlier development history. Some early patent rights may have expired or may be approaching the end of their enforceable terms, depending on the specific family, patent-term adjustment and jurisdiction.
The commercial patent position is more likely to depend on later-filed rights covering:
- Treatment of IgAN with endothelin A antagonists.
- Dosing regimens.
- Combination therapy with renin-angiotensin system inhibitors.
- Combination therapy with SGLT2 inhibitors.
- Pharmaceutical compositions and solid forms.
- Manufacturing processes.
- Patient-selection criteria based on proteinuria or kidney function.
No Orange Book-listed atrasentan patents exist because the drug is not approved. The absence of an Orange Book listing does not mean that no enforceable patents exist. It means that FDA has not yet published an approved product record against which a Paragraph IV certification could be filed.
What generic entry risks exist?
Generic entry risk is currently pre-commercial rather than immediate. If Novartis obtains approval, generic challengers could target composition, formulation, method-of-use or manufacturing patents. The most important risk factors would be:
- Whether a valid, unexpired composition patent remains at approval.
- Whether method-of-use patents cover the full commercially relevant IgAN population.
- Whether the label includes patented combination or dosing methods.
- Whether atrasentan is chemically difficult to manufacture at scale.
- Whether Novartis obtains orphan exclusivity or other regulatory protection.
- Whether a generic can launch for an unpatented indication while avoiding a protected IgAN use.
A narrow indication could make method-of-use patents more valuable. A broad label without strong patent claims would increase exposure to an early generic challenge.
How does atrasentan compare with competing IgAN drugs?
Atrasentan would enter a market that already includes targeted therapies and supportive-care standards. Its competitive position depends on renal outcome data, safety, use with other products and reimbursement.
| Product |
Company |
Mechanism |
Regulatory status in IgAN |
Commercial implication |
| Tarpeyo, targeted-release budesonide |
Calliditas, acquired by Novartis |
Local immunomodulation |
FDA approved |
Existing Novartis commercial infrastructure |
| Filspari, sparsentan |
Travere Therapeutics |
Endothelin A and angiotensin II receptor blockade |
FDA accelerated approval |
Direct mechanistic competitor |
| Jardiance, empagliflozin |
Boehringer Ingelheim/Eli Lilly |
SGLT2 inhibition |
Broad kidney indications, not IgAN-specific approval in early development period |
Supportive-care and disease-progression competitor |
| Nefecon follow-on programs |
Novartis |
Targeted-release budesonide |
Commercial and development programs |
Internal portfolio overlap |
| Atrasentan |
Novartis |
Selective endothelin A antagonism |
Investigational |
Potential combination or differentiated endothelin option |
How does atrasentan compare with sparsentan?
Sparsentan directly competes with atrasentan because both target endothelin A signaling and seek to reduce proteinuria in IgAN. Sparsentan also blocks the angiotensin II type 1 receptor, while atrasentan is selective for endothelin A.
Atrasentan could differentiate through:
- Greater selectivity for endothelin A.
- Combination use with standard renin-angiotensin system blockade.
- A separate safety profile.
- Longer-term kidney outcome data.
- Potential use after or alongside targeted-release budesonide.
- Novartis’s existing nephrology infrastructure and commercial portfolio.
Sparsentan’s first-mover advantage is meaningful, but it also establishes the clinical and payer benchmark that atrasentan must meet.
How does atrasentan compare with Tarpeyo?
Tarpeyo is an approved targeted-release formulation of budesonide that acts in the gut-associated lymphoid tissue. Atrasentan would have a different mechanism and could be used in patients who have residual proteinuria after immunomodulatory treatment.
Novartis owns both assets following the acquisition of Chinook and Calliditas. This creates a potential portfolio advantage, but it also creates internal positioning questions. Atrasentan could expand Novartis’s IgAN franchise through combination therapy, or it could compete with an existing Novartis product for the same treatment line.
What is the commercial market opportunity for atrasentan?
There is no published Novartis revenue forecast for atrasentan. The asset has no product sales and no recognized pharmaceutical revenue as of its investigational stage.
A commercial scenario can be constructed using treatment penetration and annual net price assumptions:
| Scenario |
Treated patients |
Annual net price |
Estimated annual sales |
| Conservative |
5,000 |
$75,000 |
$375 million |
| Base case |
12,500 |
$100,000 |
$1.25 billion |
| Upside |
25,000 |
$125,000 |
$3.13 billion |
These are analytical scenarios, not company guidance. Actual revenue would depend on the approved population, duration of treatment, gross-to-net discounts, payer restrictions, international pricing, diagnosis rates and use in combination.
What would drive atrasentan revenue growth?
Revenue would likely build through four stages:
- Launch and specialist adoption: Initial prescribing by nephrologists treating high-risk patients with persistent proteinuria.
- Guideline inclusion: Greater uptake if clinical guidelines recognize endothelin pathway inhibition as a standard disease-modifying approach.
- Combination expansion: Use with SGLT2 inhibitors, targeted-release budesonide or other supportive therapies.
- Geographic expansion: Regulatory approvals in Europe, Japan and other high-income markets.
The highest-value patient segment is likely to be adults with substantial residual proteinuria and preserved enough kidney function to benefit from long-term intervention.
What is the financial trajectory for Novartis and atrasentan?
Atrasentan is currently an R&D asset, not a revenue-producing product. Its financial trajectory is tied to development milestones rather than product sales.
Development-stage financial profile
The main financial characteristics are:
- No commercial revenue.
- Clinical development expenditure borne by Novartis.
- No publicly disclosed asset-specific operating profit.
- Acquisition-related value embedded in the Chinook transaction.
- Potentially significant launch costs for regulatory filings, manufacturing and medical affairs.
- Revenue concentration risk if the asset becomes a major component of Novartis’s IgAN strategy.
Novartis paid approximately $3.2 billion to acquire Chinook, giving atrasentan a substantial implied strategic value alongside other Chinook pipeline assets.[1] The acquisition price should not be treated as the standalone value of atrasentan because it included Chinook’s broader portfolio and platform capabilities.
Revenue ramp after possible approval
An approval would likely produce a gradual rather than immediate revenue ramp. Nephrology launches require diagnosis, treatment sequencing, payer authorization and evidence of durability. A plausible commercial pattern would be:
| Period |
Expected financial profile |
| Pre-approval |
R&D expense, no product revenue |
| First launch year |
Limited sales, high launch and market-access expense |
| Years 2-3 |
Expansion among high-risk IgAN patients |
| Years 4-6 |
Potential peak growth if kidney outcome data and combination use support adoption |
| Patent or exclusivity erosion |
Price pressure and volume migration to generics or competing agents |
The largest financial risk is failure to convert proteinuria reduction into accepted evidence of long-term kidney benefit. The largest upside is a label allowing broad use in patients with persistent proteinuria despite background therapy.
Which companies are challenging atrasentan?
No company has filed a Paragraph IV challenge against atrasentan because no FDA-approved atrasentan product or Orange Book listing exists.
Competitive pressure instead comes from companies developing or commercializing therapies for IgAN:
- Travere Therapeutics, with sparsentan.
- Calliditas Therapeutics, acquired by Novartis, with Tarpeyo.
- Boehringer Ingelheim and Eli Lilly, with empagliflozin kidney data.
- Otsuka and other developers pursuing immunologic or complement-pathway therapies.
- Generic manufacturers that may eventually challenge any approved product patents.
The most direct competitive issue is not a current generic challenge. It is whether atrasentan can secure a distinct place in treatment algorithms before the IgAN market becomes crowded.
What manufacturing and intellectual-property barriers affect atrasentan?
Atrasentan is a small molecule, so manufacturing complexity is generally lower than for biologics. The main barriers are likely to involve:
- Consistent production of the active pharmaceutical ingredient.
- Control of impurities and polymorphic forms.
- Salt-form and formulation stability.
- Scalable tablet manufacturing.
- Regulatory comparability for any later generic product.
- Patent protection for the commercial formulation and manufacturing process.
Unlike a biologic, atrasentan would not face biosimilar substitution risk. Its principal post-exclusivity threat would be conventional generic competition.
What patent litigation and settlement agreements affect atrasentan?
There is no known active FDA patent litigation, Paragraph IV case or generic settlement involving an approved atrasentan product. No commercial settlement agreement has been publicly disclosed that would establish a future generic launch date for atrasentan.
The relevant litigation window would begin only after an NDA approval and Orange Book listing. At that point, a Paragraph IV notice could trigger litigation under the Hatch-Waxman framework, potentially creating a 30-month stay of approval for the challenged generic, subject to statutory exceptions.
How strong is the atrasentan patent estate?
The patent estate should be viewed as potentially moderate rather than automatically strong. Older composition patents may provide limited remaining life, while newer IgAN-specific method and formulation patents could be more commercially relevant.
Patent strength will depend on:
- Claim breadth across the intended label.
- Patent expiration relative to launch.
- Freedom from invalidity and non-infringement defenses.
- Whether combination-use claims are enforceable.
- Whether the product has one dominant patent or a layered portfolio.
- The availability of regulatory exclusivity to supplement patent rights.
Novartis’s primary protection strategy is likely to combine patents with clinical differentiation, regulatory exclusivity and manufacturing know-how.
Key Takeaways
- Atrasentan hydrochloride is an investigational oral endothelin A antagonist for IgAN.
- It has no FDA approval, no Orange Book listing and no commercial revenue.
- Novartis acquired the asset through the $3.2 billion Chinook Therapeutics transaction.
- The commercial opportunity is potentially in the billion-dollar range if atrasentan wins a broad IgAN label and supports combination use.
- Sparsentan is the closest marketed mechanistic competitor.
- Tarpeyo creates both a competitive benchmark and a possible internal combination opportunity for Novartis.
- Generic entry is not an immediate issue, but future risk will depend on formulation, method-of-use and manufacturing patents.
- Atrasentan is not exposed to biosimilar competition because it is a small molecule.
- The key value inflection point is regulatory validation of proteinuria and kidney-function outcomes in the ALIGN program.
- No public Paragraph IV litigation or generic settlement currently affects atrasentan.
FAQs About Atrasentan Hydrochloride
Is atrasentan hydrochloride FDA approved?
No. Atrasentan hydrochloride remains investigational and has no FDA-approved commercial product.
Who owns atrasentan?
Novartis owns atrasentan following its acquisition of Chinook Therapeutics in 2023.
Is atrasentan the same as sparsentan?
No. Both target endothelin A signaling, but sparsentan also blocks the angiotensin II type 1 receptor. Atrasentan is designed as a selective endothelin A antagonist.
Can atrasentan be substituted with a generic drug?
No generic atrasentan product is currently approved or marketed. Generic substitution would become relevant only after approval and expiration or successful challenge of applicable exclusivity and patents.
Does atrasentan have biosimilar risk?
No. Atrasentan is a small molecule, not a biologic. Its principal future competition would come from conventional generics and other IgAN drugs.
References
-
Novartis. (2023, June 21). Novartis completes acquisition of Chinook Therapeutics. https://www.novartis.com/news/media-releases/novartis-completes-acquisition-chinook-therapeutics
-
Chinook Therapeutics. (2023). Annual report and clinical pipeline disclosures. U.S. Securities and Exchange Commission. https://www.sec.gov/
-
ClinicalTrials.gov. (n.d.). A study of atrasentan in patients with IgA nephropathy: ALIGN. U.S. National Library of Medicine. https://clinicaltrials.gov/
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.). Small business assistance: Frequently asked questions on the Hatch-Waxman amendments. https://www.fda.gov/
-
Travere Therapeutics. (2023). Filspari prescribing information. https://www.filspari.com/
-
Calliditas Therapeutics. (2023). Tarpeyo prescribing information. https://www.tarpeyo.com/
